MULPLEO

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug MULPLEO contains one active pharmaceutical ingredient (API):

1	Lusutrombopag UNII 6LL5JFU42F - LUSUTROMBOPAG
	Lusutrombopag is an orally active TPO receptor agonist. Lusutrombopag acts on the haematopoietic stem cells and on the transmembrane domain of human TPO receptors expressed in megakaryocytes, to stimulate the megakaryocyte to proliferate and differentiate via the similar signal transduction pathway for up-regulating production used by endogenous TPO, thus leading to thrombocytopoiesis.
	Read more about Lusutrombopag

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MULPLEO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BX07		B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1789836
ES	Centro de información online de medicamentos de la AEMPS	1181348001
GB	Medicines & Healthcare Products Regulatory Agency	379086
IT	Agenzia del Farmaco	047622016
LT	Valstybinė vaistų kontrolės tarnyba	1087074
PL	Rejestru Produktów Leczniczych	100416909